 |
 |
|
| ||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Many studies of obesity surgery had limitations such as no comparison group, but they suggested that patients can lose 44 to 67 lb and keep it off for up to 10 years. Weight loss after surgery has been associated with improvements in diabetes, blood pressure, and cholesterol level. However, studies suggest that up to 1.9 of every 100 patients may die because of a surgical complication. There are no studies to determine whether one of the many obesity surgery procedures is better than another, but outcomes of obesity surgery are best at centers that do many of these procedures.
Doctors should discuss surgery with obese patients who have BMIs of 40 kg/m2 or higher along with obesity-related conditions such as high blood pressure, diabetes, or sleep apnea. Patients should understand that the possible side effects of obesity surgery include surgical complications, gall bladder disease, and difficulties with digestion. Doctors and patients considering obesity surgery should seek surgeons and surgical centers with high levels of experience.
SUMMARIES FOR PATIENTS
Treating Obesity with Drugs and Surgery: A Clinical Practice Guideline from the American College of Physicians
5 April 2005 | Volume 142 Issue 7 | Page I-55
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full reports titled "Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline from the American College of Physicians," "Meta-Analysis: Pharmacologic Treatment of Obesity," and "Meta-Analysis: Surgical Treatment of Obesity." They are in the 5 April 2005 issue of Annals of Internal Medicine (volume 142, pages 525-531, pages 532-546, and pages 547-559, respectively). The first paper was written by V. Snow, P. Barry, N. Fitterman, A. Qaseem, and K. Weiss, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians; the second paper was written by Z. Li, M. Maglione, W. Tu, W. Mojica, D. Arterburn, L.R. Shugarman, L. Hilton, M. Suttorp, V. Solomon, P.G. Shekelle, and S.C. Morton; and the third paper was written by M.A. Maggard, L.R. Shugarman, M. Suttorp, M. Maglione, H.J. Sugerman, E.H. Livingston, N.T. Nguyen, Z. Li, W.A. Mojica, L. Hilton, S. Rhodes, S.C. Morton, and P.G. Shekelle.
Who developed these guidelines?
The American College of Physicians (ACP) developed these recommendations. Members of ACP are internal medicine doctors, specialists in the care of adults.
What is the problem and what is known about it so far?
Obesity leads to health problems, and obese people die younger than normal-weight people. Body mass index (BMI) is a measure of the appropriateness of a person's weight. To calculate BMI, you divide weight in kilograms by the square of height in meters (BMI = weight in kilograms/height in meters2). A BMI calculator is available at http://www.nhlbisupport.com/bmi. People with BMIs of 25 kg/m2 to 29.9 kg/m2 are overweight, and people with BMIs of 30 kg/m2 or more are obese. Treatment for obesity begins with changes in diet and exercise. However, for some patients, obesity drugs or surgery may be appropriate.
How did the ACP develop these recommendations?
The authors reviewed studies about drugs and surgical procedures used to treat obesity. They identified the weight loss and side effects that patients can expect with these treatments. These guidelines apply only to persons with BMIs of 30 kg/m2 or more.
What did the authors find?
Studies of obesity drugs had limitations such as short duration, few patients, and many patients who did not complete the study. After taking a weight loss drug for 6 to 12 months, patients lost about 11 lb or less. Previous studies have shown that this modest amount of weight loss can improve diabetes control, blood pressure, and cholesterol levels.
What does the ACP suggest that patients and doctors do?
Doctors should counsel all obese patients about diet and exercise. Doctors and patients should identify goals for weight loss, blood pressure, and blood sugar. Doctors and obese patients may consider obesity drugs when patients are unable to reach their goals with diet and exercise alone. Patients should understand the potential side effects and the lack of long-term studies of the effectiveness and safety of obesity drugs. Available obesity drugs include sibutramine, orlistat, phentermine, diethylpropion, fluoxetine, and bupropion. Doctors and patients should discuss the side effect profile of each medication to determine which drug would be best for an individual patient.
What are the cautions related to these recommendations?
Diet and exercise remain essential to the treatment of obesity, even for patients who choose medications or surgery. Recommendations may change as additional studies become available.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  S. L. Norris, D. Kansagara, C. Bougatsos, and R. Fu Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, June 3, 2008; 148(11): 855 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Samat, A. Rahim, and A. Barnett Pharmacotherapy for obesity in menopausal women Menopause Int, June 1, 2008; 14(2): 57 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R Desilets, S. Dhakal-Karki, and K. C Dunican Role of Metformin for Weight Management in Patients Without Type 2 Diabetes Ann. Pharmacother., June 1, 2008; 42(6): 817 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Eckel Nonsurgical Management of Obesity in Adults N. Engl. J. Med., May 1, 2008; 358(18): 1941 - 1950. [Full Text] [PDF]
|
|
|
|
 |
|
 K M Klein, F Theisen, S Knake, W H Oertel, J Hebebrand, F Rosenow, and H M Hamer Topiramate, nutrition and weight change: a prospective study J. Neurol. Neurosurg. Psychiatry, May 1, 2008; 79(5): 590 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Tizzano, D. S. Stribling, D. Perez-Tilve, A. Strack, A. Frassetto, R. Z. Chen, T. M. Fong, L. Shearman, P. A. Krieter, M. H. Tschop, et al. The Triple Uptake Inhibitor (1R,5S)-(+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0] Hexane Hydrochloride (DOV 21947) Reduces Body Weight and Plasma Triglycerides in Rodent Models of Diet-Induced Obesity J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1111 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Shirali and M. J. Bia Management of Cardiovascular Disease in Renal Transplant Recipients Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 491 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J F Bult, T. van Dalen, and A. F Muller Surgical treatment of obesity Eur. J. Endocrinol., February 1, 2008; 158(2): 135 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rucker, R. Padwal, S. K Li, C. Curioni, and D. C W Lau Long term pharmacotherapy for obesity and overweight: updated meta-analysis BMJ, December 8, 2007; 335(7631): 1194 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. O'Neil and T. A. Nicklas State of the Art Reviews: Relationship Between Diet/ Physical Activity and Health American Journal of Lifestyle Medicine, December 1, 2007; 1(6): 457 - 481. [Abstract] [PDF]
|
|
|
|
 |
|
 M. M. Huizinga Weight-Loss Pharmacotherapy: A Brief Review Clin. Diabetes, October 1, 2007; 25(4): 135 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Kamiji and A. Inui Neuropeptide Y Receptor Selective Ligands in the Treatment of Obesity Endocr. Rev., October 1, 2007; 28(6): 664 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W Anderson, S. B Conley, and A. S Nicholas One hundred pound weight losses with an intensive behavioral program: changes in risk factors in 118 patients with long-term follow-up Am. J. Clinical Nutrition, August 1, 2007; 86(2): 301 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Bray and F. L. Greenway Pharmacological Treatment of the Overweight Patient Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Christensen, E. M. Bartels, A. Astrup, and H. Bliddal Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis Ann Rheum Dis, April 1, 2007; 66(4): 433 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Patel and R. Pathak Rimonabant: A novel selective cannabinoid-1 receptor antagonist for treatment of obesity Am. J. Health Syst. Pharm., March 1, 2007; 64(5): 481 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fujioka and M. W. Lee Pharmacologic Treatment Options for Obesity: Current and Potential Medications Nutr Clin Pract, February 1, 2007; 22(1): 50 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Freemark Pharmacotherapy of Childhood Obesity: An evidence-based, conceptual approach Diabetes Care, February 1, 2007; 30(2): 395 - 402. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Byers and R. L. Sedjo Public Health Response to the Obesity Epidemic: Too Soon or Too Late? J. Nutr., February 1, 2007; 137(2): 488 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M H Bennett, S. Mehta, and M. Rhodes Surgery for morbid obesity Postgrad. Med. J., January 1, 2007; 83(975): 8 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Goren Hyperthyroidism Associated With Topiramate Treatment Psychosomatics, December 1, 2006; 47(6): 529 - 530. [Full Text] [PDF]
|
|
|
|
|
|
K. E. Foster-Schubert and D. E. Cummings Emerging Therapeutic Strategies for Obesity Endocr. Rev., December 1, 2006; 27(7): 779 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Day and C. J Bailey Review: Pharmacological approaches to reduce adiposity The British Journal of Diabetes & Vascular Disease, May 1, 2006; 6(3): 121 - 125. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Lopez, C. J. Lelliott, S. Tovar, W. Kimber, R. Gallego, S. Virtue, M. Blount, M. J. Vazquez, N. Finer, T. J. Powles, et al. Tamoxifen-Induced Anorexia Is Associated With Fatty Acid Synthase Inhibition in the Ventromedial Nucleus of the Hypothalamus and Accumulation of Malonyl-CoA. Diabetes, May 1, 2006; 55(5): 1327 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chounta, S. Tsiodras, S. Zouridakis, M. Doumas, and H. Giamarellou Sibutramine Use Associated with Reversible Hepatotoxicity Ann Intern Med, November 15, 2005; 143(10): 763 - 764. [Full Text] [PDF]
|
|
|
|
|
|
D. T Villareal, C. M Apovian, R. F Kushner, and S. Klein Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society Am. J. Clinical Nutrition, November 1, 2005; 82(5): 923 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Wolfe and J. M. Morton Weighing In on Bariatric Surgery: Procedure Use, Readmission Rates, and Mortality JAMA, October 19, 2005; 294(15): 1960 - 1963. [Full Text] [PDF]
|
|
|
|
 |
|
 K. A Kennel Review: several pharmacological therapies promote modest weight loss Evid. Based Med., October 1, 2005; 10(5): 140 - 140. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Robbins Guidelines for the Treatment of Obesity AAP Grand Rounds, September 1, 2005; 14(3): 31 - 32. [Full Text] [PDF]
|
|
|
|
 |
|
 Endocrinology & Metabolism News, May 2005 J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 16a - 16a. [Full Text] [PDF]
|
|
|
|
 |
|
 Managing Obesity: Clinical Practice Guideline from the ACP Journal Watch (General), April 26, 2005; 2005(426): 1 - 1. [Full Text]
|
|
|
|
|
|
A. Tonks Short cuts: What's new in the other general journals BMJ, April 16, 2005; 330(7496): 867 - 868. [Full Text] [PDF]
|
|
|
|
|
|
V. Snow, P. Barry, N. Fitterman, A. Qaseem, K. Weiss, and for the Clinical Efficacy Assessment Subcommittee Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, April 5, 2005; 142(7): 525 - 531. [Abstract] [Full Text] [PDF]
|
|
Read all Rapid Responses
| ||||||||||||||||||||||||||||
Article
